Nephrotic Syndrome Treatment Market Size, Share, By Drugs (Sodium Restriction Drugs, Fluid Restriction Drugs, Loop Diuretics, Angiotensin-Converting Enzyme Inhibitor, and Others), Type (Primary Nephrotic Syndrome, Secondary Nephrotic Syndrome, Congenital Nephrotic Syndrome, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy), and Region - Trends, Analysis, and Forecast till 2035

• The Nephrotic syndrome treatment market size is envisioned to flourish at USD 6.8 Billion by 2035.
• The market size was benefited USD 2.8 Billion in 2024.
• Target market is expected to grow at a CAGR of 9.5%.

Nephrotic syndrome is a condition in which kidney release an excessive amount of protein (proteinuria) in urine (pee). The market is growing primarily due to the rising prevalence of nephrotic syndrome, particularly among pediatric and elderly populations, coupled with increased awareness about the condition, growing understanding of its underlying causes, and the development of more targeted and effective treatment options, including novel immunosuppressant and biologics, which are improving patient outcomes and driving demand for innovative therapies.

AI Contribution in the Target Market:

Artificial intelligence (AI) is being used to speed up drug discovery for nephrotic syndrome and other complex diseases. AI can help identify new uses for existing drugs and shorten the time it takes to get them to patients.

Key Drivers of Target Market:

Increasing Cases of Nephrotic Syndrome may Drive Market Expansion

By expanding the patients in need of treatment, a growing number of nephrotic syndrome cases directly contributes to the growth of the nephrotic syndrome market by increasing demand for both new and existing therapies, diagnostics, and associated healthcare services meant to manage the condition.

• For instance, according to the data published by Kauvery Hospital, around 15,000 children are diagnosed with the condition every year. Common primary causes of nephrotic syndrome are minimal change nephropathy and focal glomerulosclerosis. Secondary causes include systemic diseases, such as diabetes mellitus, lupus erythematosus, and amyloidosis.

Restraints:

Side Effects of Nephrotic Syndrome Treatment may Hindered Market Expansion

Due to the serious side effects of nephrotic syndrome treatments, such as growth impairment, weight gain, increased infection risk, mood swings, cataracts, and bone density loss, especially the widespread use of corticosteroids, significantly limit market growth. These side effects can discourage patients from consistent treatment and raised concerns about long-term quality of life, which in turn affects the market adoption of new therapies.

• Counterbalance Statements: To manage side effects from nephrotic syndrome treatment, which often includes steroids, focus on dietary adjustments, such as a low-sodium diet, monitoring fluid intake, managing cholesterol with medication, and addressing potential bone density loss, and so on.

Opportunities:

Nephrotic Syndrome Pipeline Therapies Expected to Boost the Market Growth

Companies across the globe are diligently working toward the development of novel treatment nephrotic syndrome therapies. The anticipated launch of various emerging nephrotic syndrome therapies are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the nephrotic syndrome treatment market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

The market for nephrotic syndrome is classified on the basis of drugs, Types, distribution channel, and region.

Drugs

The market, by drugs, is segmented into sodium restriction drugs, fluid restriction drugs, loop diuretics, angiotensin-converting enzyme inhibitor, and others. Angiotensin-converting enzyme (ACE) inhibitors hold the dominant nephrotic syndrome treatment market share as they are highly effective in managing proteinuria (excess protein in urine), a key feature of nephrotic syndrome, and others.

Type

Assenting to type, the market is segmented into primary nephrotic syndrome, secondary nephrotic syndrome, congenital nephrotic syndrome, and others. Among these, the primary nephrotic syndrome segment prevail the market as it represents the most common form of the disease, primarily caused by conditions, such as minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS).

Distribution Channel

The market through distribution channel is categorized into hospital pharmacy, online pharmacy and retail pharmacy. The retail pharmacy distribution channel is superior as compared to others, primarily due to its widespread accessibility, convenience for patients, and ability to cater to chronic medication needs compared to hospital pharmacies and online pharmacies.

Regional

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: North America currently holds the largest market share for Nephrotic Syndrome treatments with 37.5%. The growth is attributed to the high prevalence of the condition, robust healthcare infrastructure, and the presence of leading pharmaceutical companies in the region.

• For instance, according to the data published by NephCure, Inc., In the U.S., adult incidence of primary nephrotic syndrome each year is 3 out of every 100,000 individuals. 2-4 out of every 100,000 children are diagnosed with primary nephrotic syndrome each year in North America.

Asia Pacific: the Asia Pacific region is considered the fastest growing market for nephrotic syndrome treatment, primarily driven by a rising prevalence of diabetes, a growing patient population, and increasing access to advanced healthcare services within the region.

Nephrotic Syndrome Treatment Market Report Scope:

Segmentation:

By Drugs:

• Sodium Restriction Drugs
• Fluid Restriction Drugs
• Loop Diuretics
• Angiotensin-Converting Enzyme Inhibitor
• Others

By Type:

• Primary Nephrotic Syndrome
• Secondary Nephrotic Syndrome
• Congenital Nephrotic Syndrome
• Others

By Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Companies’ active in nephrotic syndrome treatment market are Mallinckrodt company, Novartis AG, Cerium Pharmaceuticals, Inc., Max Healthcare, Chugai Pharmaceutical Co., Ltd., and among others. These key players focusing on strategies such as focusing on developing medications to manage proteinuria (excess protein in urine) with drugs, such as ACE inhibitors and ARBs, utilizing corticosteroids to reduce inflammation, employing diuretics to control edema (swelling), managing cholesterol levels with statins, and so on.

List of Key Players in the Market:

• Mallinckrodt company
• Novartis AG
• Cerium Pharmaceuticals, Inc.
• Chugai Pharmaceutical Co., Ltd.
• Aurinia Pharmaceuticals Inc.
• Sanofi
• Regeneron Pharmaceuticals Inc.
• Asahi Kasei Corporation
• Eli Lilly and Company
• Merck & Co., Inc.
• Pharmaceuticals, Inc.
• Baxter International Inc.

• In November 2024, Vera Therapeutics, Inc., a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, partnered with the University of Michigan on the Nephrotic Syndrome Study Network (NEPTUNE) Match project. In partnership with Vera Therapeutics, NEPTUNE Match will inform potential participants about the PIONEER study.
• In August 2023, a new study published in Science Translational Medicine, researchers at the University of Bristol have shown that just one dose of gene therapy targeting cells in the kidney called podocytes has the potential to cure steroid-resistant nephrotic syndrome. The research team proposed that gene therapy could be applied to correct these faults. The most common fault is in one gene that codes for a protein called podocin, which is essential for the function of cells called podocytes (a critical part of the kidney’s filtration unit).
• In November 2021, ANI Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) for Purified Cortrophin Gel for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (MS) and rheumatoid arthritis (RA), in addition to excess urinary protein due to nephrotic syndrome.

Analyst View:      

The development of more targeted and efficient treatment options, such as novel immunosuppressant and biologics, which are improving patient outcomes and driving demand for innovative therapies, along with the increased awareness of the condition and its underlying causes, are the main factors driving the market's growth.

More Related Reports

Short Bowel Syndrome Market
Irritable Bowel Syndrome Market
Bartter Syndrome Treatment Market
Cushing's Syndrome Treatment Market
Alopecia Treatment Market